Garrett McFadden celebrates 10 years of mental health initiative McFadden's Movement by Ryan Drury - Guelph Storm - Canadian Hockey League

Passed away peacefully, at Champlain Manor, Orillia, on Thursday, October 15, 2026, in her 94th year. Alba McFadden, beloved wife of the late Eldon McFadden. Longtime friend of the late Jack Elgie. Sister of the late Aubrey McMillan. Dear mother of Rose Marie Baye and husband Garry of Uptergrove, Theresa Ruttle and husband Brian of Orillia and the late Colette McFadden. Loved grandmother of Frances Szalay and husband Mike. Great grandmother of Amber and Megan Szalay. The late Alba McFadden will rest at the Mundell Funeral Home, 79 West St., N., Orillia, on Friday, October 23rd, 2026, from 11 am until time of service in the chapel at 12 Noon. Cremation to follow. Interment to take place at Knox Cemetery at a later date. If desired, memorial donations may be made to the Charity of One's Choice. Members of the Women of the Moose Chapter 659 Orillia, are asked to gather for service on Friday at 12 noon.

Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.